NASDAQ:ADTX

ADiTx Therapeutics Stock Forecast, Price & News

$2.73
-0.09 (-3.19 %)
(As of 06/18/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.70
$2.84
50-Day Range
$2.20
$3.20
52-Week Range
$1.62
$9.58
Volume110,900 shs
Average Volume2.02 million shs
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
BetaN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ADTX News and Ratings via Email

Sign-up to receive the latest news and ratings for ADiTx Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


ADiTx Therapeutics logo

About ADiTx Therapeutics

ADiTx Therapeutics, Inc., a biotech company, develops technologies focuses on improving the health of the immune system through immune reprogramming and monitoring. It develops AditxtScore that allows individuals to understand, manage, and monitor their immune profiles in order to be informed about attacks on or by their immune system; and Apoptotic DNA Immunotherapy, a nucleic acid-based technology that utilizes an approach that mimics the way the body naturally induces tolerance to its own tissues. The company is also developing ADi products for organ transplantation, including skin grafting, autoimmune diseases, and allergies. ADiTx Therapeutics has a license agreement with Loma Linda University and Leland Stanford Junior University. ADiTx Therapeutics, Inc. was incorporated in 2017 and is headquartered in Mountain View, California.

Headlines

See More Headlines

Industry, Sector and Symbol

Sales & Book Value

Profitability

Debt

Price-To-Earnings

Miscellaneous


MarketRank

Overall MarketRank

1.71 out of 5 stars

Medical Sector

284th out of 2,100 stocks

Pharmaceutical Preparations Industry

138th out of 831 stocks

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











ADiTx Therapeutics (NASDAQ:ADTX) Frequently Asked Questions

Is ADiTx Therapeutics a buy right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for ADiTx Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADiTx Therapeutics stock.
View analyst ratings for ADiTx Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than ADiTx Therapeutics?

Wall Street analysts have given ADiTx Therapeutics a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but ADiTx Therapeutics wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting ADiTx Therapeutics?

ADiTx Therapeutics saw a increase in short interest in the month of May. As of May 28th, there was short interest totaling 543,100 shares, an increase of 18.5% from the May 13th total of 458,300 shares. Based on an average trading volume of 291,500 shares, the short-interest ratio is currently 1.9 days. Currently, 4.9% of the shares of the stock are sold short.
View ADiTx Therapeutics' Short Interest
.

How were ADiTx Therapeutics' earnings last quarter?

ADiTx Therapeutics, Inc. (NASDAQ:ADTX) announced its earnings results on Tuesday, May, 11th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.21) by $0.25.
View ADiTx Therapeutics' earnings history
.

Who are ADiTx Therapeutics' key executives?

ADiTx Therapeutics' management team includes the following people:
  • Mr. Amro A. Albanna, Co-Founder, Chairman, Pres & CEO (Age 51, Pay $252k)
  • Dr. Shahrokh Shabahang D.D.S., M.S., Ph.D., Co-founder, Chief Innovation Officer, Sec. & Director (Age 58, Pay $210k)
  • Ms. Corinne D. Pankovcin CPA, CPA, Chief Financial Officer (Age 55, Pay $450k)
  • Ms. Rowena Albanna, Chief Operating Officer (Age 55)
  • Mr. Thomas J. Farley, Principal Accounting Officer & Controller (Age 47)
  • Mr. Suneet Uberoi, Chief Communications Officer
  • Mr. Anthony Voorhies, Head of Bus. Devel. - AditxtScore
  • Dr. Dolly B. Tyan Ph.D., Sr. VP of Clinical Devel. – Transplantation

Who are some of ADiTx Therapeutics' key competitors?

What other stocks do shareholders of ADiTx Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ADiTx Therapeutics investors own include Tesla (TSLA), Dynavax Technologies (DVAX), The Boeing (BA), CrowdStrike (CRWD), Genius Brands International (GNUS), Nikola (NKLA), Square (SQ), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV) and Arbutus Biopharma (ABUS).

What is ADiTx Therapeutics' stock symbol?

ADiTx Therapeutics trades on the NASDAQ under the ticker symbol "ADTX."

Who are ADiTx Therapeutics' major shareholders?

ADiTx Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Geode Capital Management LLC (0.00%), Virtu Financial LLC (0.00%), Northern Trust Corp (0.00%) and XTX Topco Ltd (0.00%). Company insiders that own ADiTx Therapeutics stock include Corinne Pankovcin, Shahrokh Shabahang and Thomas J Farley.
View institutional ownership trends for ADiTx Therapeutics
.

Which major investors are buying ADiTx Therapeutics stock?

ADTX stock was purchased by a variety of institutional investors in the last quarter, including Geode Capital Management LLC, Virtu Financial LLC, Northern Trust Corp, and XTX Topco Ltd. Company insiders that have bought ADiTx Therapeutics stock in the last two years include Corinne Pankovcin, Shahrokh Shabahang, and Thomas J Farley.
View insider buying and selling activity for ADiTx Therapeutics
or or view top insider-buying stocks.

How do I buy shares of ADiTx Therapeutics?

Shares of ADTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ADiTx Therapeutics' stock price today?

One share of ADTX stock can currently be purchased for approximately $2.73.

How many employees does ADiTx Therapeutics have?

ADiTx Therapeutics employs 43 workers across the globe.

What is ADiTx Therapeutics' official website?

The official website for ADiTx Therapeutics is www.aditxt.com.

Where are ADiTx Therapeutics' headquarters?

ADiTx Therapeutics is headquartered at 2569 WYANDOTTE ST. SUITE 101, MOUNTAIN CA, 94043.

How can I contact ADiTx Therapeutics?

ADiTx Therapeutics' mailing address is 2569 WYANDOTTE ST. SUITE 101, MOUNTAIN CA, 94043. The company can be reached via phone at 650-870-1200.


This page was last updated on 6/21/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.